PRs are one of the most cost effective marketing tools online! Signup Today!

Posts made in May, 2016

Analysis: Cryptic press release by police cushions blow for Sara Netanyahu

By on May 31, 2016 in Press Release |

It wasn’t their first rodeo, but the crime reporters in the police spokesman’s group were shocked nonetheless. The press release sent out by the police on Sunday – more cryptic treasure map than transparent statement to the media – dealt with one of the most high-profile cases in years, and left the reporters confounded, ill-informed and furious. The statement that police had finished their probe of the Prime Minister’s Residence case left out the very details that are included in every such statement – was there enough evidence found to recommend an indictment, and if so, against whom? Without naming names or giving up any information whatsoever about the findings of the investigation, the statement itself was all but worthless, a sports page without the scores. Once the statement was released, the WhatsApp page lit up with texts by reporters including the following: “We don’t need your hints. Is there or isn’t there a recommendation?” “You’re trying to pull one over on us and this is causing damage to all citizens of Israel.” “This is an anti-democratic action!” From the outside, it may appear to be an internal dispute between the media and a police force reluctant to cooperate. But there’s something much more troubling at play. Presumption of innocence is a principle of crucial importance, as is the privacy of suspects. This equation changes, however, when the suspect in question is a public figure, especially one who is married to the most powerful person in the country, and stands accused of misusing taxpayers’ money. In these cases, it is the responsibility of the police to provide information to the public they serve about allegations of illegal activity by their elected officials and members of their inner circle, no matter how it may affect the reputation or blood pressure of powerful people. Other than in the case of Sara Netanyahu, police have maintained this policy as of late, in particular regarding the litany of corruption investigations against local authority heads in recent years. To make an even more glaring comparison, just last week they clarified that they found evidence against actor Moshe Ivgy, including many cases of sexual misconduct, and also gave their recommendation regarding a spreading case of...

Read More

Press Release from Business Wire : Wipro Limited

By on May 30, 2016 in Press Release |

EAST BRUNSWICK, (BSW) – Wipro Limited (NYSE:WIT)(BSE: 507685)(NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has received the Citi Lean Partner award for 2015 from Citi, in recognition of its high levels of service and performance. The Lean Partner Award recognizes a supplier that has supported Citi in the execution of its re-engineering objectives and supported its effort to drive client-centric process redesign throughout the company – improving the way Citi operates. The award also recognizes the supplier who has most embodied the spirit of Lean, a continuous improvement program with tangible and measurable benefits as it relates to purpose (rapid and consistent turnaround time for services delivered), quality, efficiency, controls and overall customer experience. On receiving the award from Citi,Rishad Premji, Chief Strategy Officer and Member of the Board, Wipro Limitedsaid, “We have enjoyed a long-standing and fruitful relationship with Citi and are delighted to be recognized with this award. This award is a testimony to our alignment with Citi’s objectives.” About Wipro Ltd. Wipro Ltd. (NYSE:WIT) is a leading information technology, consulting and business process services company that delivers solutions to enable its clients do business better. Wipro delivers winning business outcomes through its deep industry experience and a 360 degree view of “Business through Technology.” By combining digital strategy, customer centric design, advanced analytics and product engineering approach, Wipro helps its clients create successful and adaptive businesses. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, Wipro has a dedicated workforce of over 160,000, serving clients in 175+ cities across 6 continents. For more information, please visitwww.wipro.com. Forward-looking and Cautionary Statements Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract...

Read More

Press Release from Business Wire : Samsung Bioepis Co., Ltd.

By on May 30, 2016 in Press Release |

INCHEON, (BSW) – Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Flixabi- a biosimilar version of Remicade(infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160529005047/en/ “With this approval, we are taking another important step in broadening affordable, high-quality biologic treatment options across Europe,” said Christopher Hansung Ko, President CEO of Samsung Bioepis. “The focused dedication of everyone at Samsung Bioepis has now yielded in the European approval for another biosimilar referencing a most widely used biologic medicine. Our commitment to quality and speed has brought us this far in just over four years, and our relentless drive for healthcare innovation will continue as we further advance one of the industry’s largest biosimilar pipelines.” The EC approval of Flixabiapplies to all 28 European Union (EU) member states as well as the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. In accordance with a commercialization agreement signed in 2013 between Samsung Bioepis and Biogen, Biogen will lead the commercialization and distribution of Flixabiin the EU and EEA member states. In a 54-week Phase III clinical study, Flixabishowed comparable safety and equivalent efficacy to Remicade, as evidenced in ACR20 response rate of 65.3% in the Flixabiarm versus 69.2% in the Remicadearm at Week 54, fully supporting the 30-week study results of 64.1% and 66.0%, respectively. The Flixabistudy randomized 584 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries. Samsung Bioepis continues to advance a broad pipeline of 13 biosimilar candidates, which includes the following six first-wave product candidates that cover the therapeutic areas of immunology, oncology and diabetes: — SB4 investigational biosimilar candidate referencing Enbrel® (etanercept) — SB2 investigational biosimilar candidate referencing Remicade® (infliximab) — SB5 investigational biosimilar candidate referencing Humira® (adalimumab) — SB9 (MK-1293) investigational biosimilar candidate referencing Lantus® (insulin glargine) — SB3 investigational biosimilar candidate referencing Herceptin® (trastuzumab) — SB8 investigational biosimilar candidate referencing Avastin® (bevacizumab) Samsung Bioepis is solely responsible for the development and manufacture of all immunology and oncology biosimilar candidates in its pipeline, as well as global clinical trials...

Read More